EC
CRL icon

EntryPoint Capital’s Charles River Laboratories CRL Stock Holding History

EntryPoint Capital’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,033
Closed -$318K – 690
2025
Q3 		$318K Buy
+2,033
New +$323K 0.12% 346
2024
Q4 		– Sell
-1,144
Closed -$225K – 770
2024
Q3 		$225K Buy
+1,144
New +$238K 0.13% 390

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

EntryPoint Capital's CRL Position: Q4 2025 in Review

EntryPoint Capital sold out of Charles River Laboratories (CRL) in Q4 2025, closing a stake of 2,033 shares — an estimated $318K sold.

EntryPoint Capital first reported a position in CRL in Q3 2024 and held it in 2 quarters. The position peaked at $318K in Q3 2025. 583 funds tracked by Wall St. Rank hold CRL as of Q4 2025.

  • EntryPoint Capital reported no remaining Charles River Laboratories position as of Q4 2025 after selling out during the quarter.
  • EntryPoint Capital sold 2,033 Charles River Laboratories shares in Q4 2025, an estimated $318K.
  • EntryPoint Capital first reported a position in Charles River Laboratories in Q3 2024 and held it in 2 quarters.
  • EntryPoint Capital's Charles River Laboratories position peaked at $318K in Q3 2025.
  • 583 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2025.

Based on EntryPoint Capital's 13F filing for Q4 2025, filed 12 Feb 2026.